Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023890 (cirrhosis)
 42,195 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The HCV, a single stranded RNA virus belonging to the family of flavivirus, has been identified as the probable cause of the majority of cases of transfusion-associated NANB hepatitis and community-acquired NANB hepatitis in Japan. The hepatitis virus is present in a least 2% of the blood donor population and is extremely common in high risk groups, such as hemophiliacs and hemodialysis patients. The contribution of HCV infection to sporadic, acute and chronic hepatitis, liver cirrhosis and primary liver cancer has been established. Furthermore anti-HCV in 20% of alcoholic patients with liver injury suggest that HCV may be etiologically associated with liver disease previously attributed to other causes. Therapy of acute and chronic liver disease associated with HCV infection is likely to be undertaken with recombinant IFN alpha in the future to prevent the progression of the disease from acute hepatitis to chronic hepatitis, and from chronic hepatitis to liver cirrhosis or primary liver cancer. However the prevention of HCV infection will be the goal, in addition to screening of donor blood and exclusion to a large degree of positive units likely to decrease the incidence of post-transfusion hepatitis.
 ...
PMID:Hepatitis C: basic and clinical studies. 131 82

Tissue plasminogen activator (t-PA) levels in plasma or serum were studied in 416 patients with liver diseases: acute hepatitis (AH, n = 30); fulminant hepatitis (FH, n = 36); chronic inactive hepatitis (CIH, n = 57); chronic active hepatitis (CAH, n = 39); compensated liver cirrhosis (cLC, n = 78); decompensated liver cirrhosis (dLC, n = 84); hepatocellular carcinoma (HCC, n = 64); advanced hepatocellular carcinoma (aHCC, n = 28); and compared with that of a control group (n = 106) of healthy subjects. The t-PA levels showed significant increase in patients with AH, FH, CAH, cLC, dLC and HCC, compared with normal controls. The abnormal rates in t-PA levels (higher than 8.3 ng/ml) for each type of liver diseases were 86.1% in FH, 46.2% in CAH, 50% in cLC, 85.7% in dLC, 67.2% in HCC, and 89.3% in aHCC. t-PA levels tended to be higher in more advanced liver diseases. t-PA levels significantly correlated positively with plasminogen activator inhibitor (PAI-1) in AH, cLC, dLC, HCC and aHCC, and negatively with plasmin alpha 1-plasmin inhibitor complex (PIC), plasminogen (Plg), FDP, AT III and alpha 2-plasmin inhibitor (alpha 2-PI) in dLC, prothrombin time (PT) and fibrinogen (Fbg) in HCC. t-PA levels in patients with FH, CAH and dLC were significantly higher than those in patients with AH, CIH and cLC, respectively. Moreover, the changes of t-PA levels in the clinical courses of various liver diseases revealed that t-PA levels increased sensitively with progression of liver diseases or in advanced liver diseases.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Clinical evaluation of tissue plasminogen activator (t-PA) levels in patients with liver diseases. 131 84

Hepatocellular carcinoma is endemic in Africa, where in the incidence of the disease in males ranges from 20-100,000 per annum. The tumor tends to occur at a younger age compared to the age of presentation in Europeans or Chinese. The majority of African patients with HCC are HBsAg positive, but HBsAg is more commonly detected in younger vs older patients. Approximately 30% of patients are anti-HCV positive. Both these chronic virus infections may induce disease via the development of cirrhosis. Other environmental factors including carcinogens such as aflatoxin may act as co-factors. Resection rates for hepatocellular carcinoma are low in this population group, and screening for small tumours is not generally undertaken in Africa.
 ...
PMID:Hepatocellular carcinoma in Africans. 131 16

From 1964 to 1990, 318 cases of primary liver cancer were treated by surgery. Of them, 227 (71.3%) were complicated with cirrhosis to various degrees: mild, moderate and severe. The lesions in the latter group was greater than 10 cm in 3 patients, 5-10 cm in 7 and less than 5 cm in 17. All were confirmed by histopathology to be hepatocellular carcinoma. The method of operation was partial hepatectomy in 23 patients and intra-tumoral absolate alcohol injection supplemented by microwave coagulation in 4. The amount of absolate alcohol ranged from 18 to 30 ml with an average of 24 ml. The chief complications were jaundice and ascites (13 patients--48%) and gastrointestinal hemorrhage (3 patients--11%). Operative mortality was 15% (4/27). The 1-, 3- and 5-year survival rates were 82%, 39% and 10%.
 ...
PMID:[Surgical treatment of primary liver cancer complicated with cirrhosis]. 131 92

Fifty-four patients with cirrhosis, found to have a space-occupying lesion in the liver by ultrasound (US), underwent US-assisted biopsy of the lesion and were then followed prospectively to define outcome and survival. Histologic examination revealed hepatocellular carcinoma in 26 patients, while five had liver cell dysplasia without hepatocellular carcinoma and 23 had no evidence of tumor or of dysplasia. All five patients with an initial diagnosis of dysplasia developed hepatocellular carcinoma during follow-up and their survival curve was similar to that of patients with liver cancer and significantly worse than that of patients without dysplasia or tumor. There were five false-negative cases of hepatocellular carcinoma among the patients with negative histology. Overall, US-assisted liver biopsy diagnosed malignancy with a sensitivity of 72%, which increased to 86% when dysplasia was considered a pre-neoplastic lesion.
 ...
PMID:Space-occupying lesions of the liver detected by ultrasonography and their relation to hepatocellular carcinoma in cirrhosis. 132 Jan 76

A Nigerian series of 890 patients with primary liver cell carcinoma, seen during the recent three years, has been examined with a view to establishing the natural history of the tumour in untreated cases. There were 60 males and the mean age of all the patients was 50 years. Hepatitis B surface antigen was positive in 70 pc of tested patients and there were higher pathologic levels of aflatoxins in these patients when compared to normal controls. Liver cirrhosis was associated with 81 pc of patients. Alcohol and smoking were unlikely to be aetiologically important in these patients. The macroscopic type of tumour was mainly diffusely nodular and the commonest microscopic pattern was the characteristic trabecular pattern. Metastases were present in 52 pc of the patients and were mainly to the lungs. Due to late presentation and underlying cirrhosis, most patients were critically ill with high incidence of ascites, jaundice and hepatic precoma. The mean survival time of all patients was six months after onset of the initial symptoms to death and only three weeks after admission to death. The major causes of death were advanced cancer in 78 pc, hepatic failure in 48 pc and rupture of tumour, 39 pc. These observations clearly show that the prognosis of liver cancer is dismal in this environment, as elsewhere. Medical education on earlier presentation in hospital and early operative removal of the tumour should be emphasised. It is suggested that an attempt through immunisation should be employed to reduce the incidence of liver cancer in the population.
 ...
PMID:The natural history of primary liver cell carcinoma: a study of 89 untreated adult Nigerians. 132 87

The purpose of this study was to retrospectively analyse the results of 1102 primary liver cancer (PLC) patients who underwent liver resection in the past thirty years and to research some effective approaches for improving the longterm effect of PLC treatment. Ninety five percent were hepatocellular carcinoma (HCC), 85.2% with cirrhosis of hepatitis and 25.6% with tumor equal to or smaller than 5 cm in diameter. The mortality rate (MR) within 1 month after operation was 1.8%, the operative MR was 8.8% before 1977 and only 0.4% after that. The total 5-year survival rate (SR) was 28.4% while in the group of small tumor (less than or equal to 5 cm), it was 75.0%. Our experience is as follows: (1) Early diagnosis and early resection of PLC is the key point for improving the operative result of long-term survival. In 282 cases of small cancer, tumor resection rate was 90.0%. Of 48 cases with tumor equal to or smaller than 3 cm in diameter, the 5-year SR was 83.3%. (2) Rehepatectomy for recurrent liver cancer is an important approach for improving the surgical result. In our series, recurrent rate within 5 years postoperation was 72.3% in larger tumor group and 34.5% in small tumors. There were 78 cases undergoing reoperation in a total number of 170 times of rehepatectomy with 54.7% of 5-year SR, after the 1st operation and 34.6% after the 2nd one. (3) For unresectable large tumors, two-stage operation is an important development in liver surgery. We had 26 cases of such patients with 60.0% of 5-year SR. (4) Improvement of operating techniques plays an important role in reducing postoperative complications, lowering operative mortality and obtaining better operative result. (5) Postoperative comprehensive treatment is also important for solidating operative effect and preventing tumor recurrence.
 ...
PMID:Surgical approaches for improving the operating results of primary liver cancer. 132 42

The prevalence of antibodies to hepatitis C virus (HCV) was investigated in 129 patients with chronic liver disease (85 with chronic active hepatitis and 44 with cirrhosis) and 53 patients with hepatocellular carcinoma. The commercially available second generation anti-HCV enzyme immunoassay kit was used. Antibodies to hepatitis C virus were detected in 16.2% of the patients with chronic liver disease and in 15.1% with hepatocellular carcinoma. Of the HCV positive patients in all groups 51.7% were positive for hepatitis B virus (HBV) markers indicating present or past infection. Prevalence of HBV markers in all the three groups (CAH, cirrhosis and HCC) was higher as compared with anti-HCV prevalence. These results suggest that HCV infection may not be a major cause of chronic liver disease and hepatocellular carcinoma in India and indicate the presence of other aetiological agents.
 ...
PMID:Prevalence of hepatitis C virus antibodies in chronic liver disease and hepatocellular carcinoma patients in India. 132 97

High-differentiated hepatocellular carcinoma (h-d HCC) is a not frequent hepatic tumour but its outcome may be beneficial when treated properly. Two cases of h-d HCC recognized on the basis of postoperative histopathology are reported. We have discussed the role of fine needle biopsy in distinguishing h-d HCC from liver adenoma, and we have attempted to outline the diagnostic approach in clinically silent hepatic tumours which are not associated with cirrhosis or elevated alfa-fetoprotein plasma level.
 ...
PMID:[Highly differentiated cancer or adenoma of the liver: diagnostic approach in highly differentiated epithelial tumors of the liver]. 132 1

PAP technique and rabbit anti-X serum were used to detect the X protein in tumor and nontumor liver tissues from 34 patients with HCC. The positive rate of the X protein in both tissues were 94.1% and 84.4% respectively. Of the 34 patients with HCC, 27 were complicated by liver cirrhosis, in whom 92.6% were X protein positive in liver cells. It was found that almost all of the liver cells adjacent to the tumor tissue showed strong positive staining. The high frequency and predominant expression of X protein in HCC and liver cirrhosis tissues indicated that X protein may play an important role in hepatocarcinogenesis. X protein was detected in 17.2% of the patients with CAH, which suggested the risk of transformation from CAH to cirrhosis and/or HCC. X protein was first found in bile duct epithelial cells in 59.4% of the patients with HCC, and 6 of 34 HCC were combined with bile duct carcinoma, and some cancer cells were found positive for X protein. It seems that X protein may also be a potential factor in the oncogenesis of bile duct carcinoma.
 ...
PMID:[Expression of hepatitis B virus X protein in tumor and nontumor tissues of patients with hepatocellular carcinoma (HCC)]. 132 50


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>